Feature Channels: Pharmaceuticals

Filters close
17-Jul-2020 5:35 PM EDT
Common Blood Test Identifies Benefits and Risks of Steroid Treatment in COVID-19 Patients
Albert Einstein College of Medicine and Montefiore Health System

A new study led by Albert Einstein College of Medicine and Montefiore Health System confirms the findings of the large scale British trial of steroid use for COVID-19 patients and advances the research by answering several key questions: Which patients are most likely to benefit from steroid therapy? Could some of them be harmed? Can other formulations of steroids substitute for the agent studied in the British trial? The research was published today in the Journal of Hospital Medicine.

Released: 21-Jul-2020 12:40 PM EDT
Next-Generation Risk Assessment, Antimicrobials, and More Featured in July 2020 Toxicological Sciences
Society of Toxicology

Published in this month’s edition of Toxicological Sciences are articles on biotransformation, toxicokinetics, and pharmacokinetics; developmental and reproductive toxicology; nanotoxicology; and more.

   
Released: 21-Jul-2020 12:15 PM EDT
Aerosol modeling targets sinus inflammation
South Dakota State University

New instructions for using nasal sprays may help deliver at least eight times more inflammation-reducing medicine to diseased sinus tissues.

Released: 21-Jul-2020 11:25 AM EDT
Nitric Oxide May Slow Progression of COVID-19
George Washington University

Researchers at the George Washington University and Albert Einstein College of Medicine published a review in the journal Nitric Oxide suggesting that nitric oxide treatment can be pivotal in the fight against SARS-CoV-2.

Released: 21-Jul-2020 8:00 AM EDT
Sanford Burnham Prebys receives CIRM award for COVID-19 research
Sanford Burnham Prebys

Sanford Burnham Prebys Medical Discovery Institute has received an award from the California Institute for Regenerative Medicine (CIRM) to advance promising drug candidates for COVID-19. The research team will test two existing drugs against “mini lungs in a dish” that have been infected with SARS-CoV-2.

Released: 20-Jul-2020 5:35 PM EDT
"Love hormone" oxytocin could be used to treat cognitive disorders like Alzheimer's
Tokyo University of Science

Alzheimer's disease is a progressive disorder in which the nerve cells (neurons) in a person's brain and the connections among them degenerate slowly, causing severe memory loss, intellectual deficiencies, and deterioration in motor skills and communication.

Released: 20-Jul-2020 2:35 PM EDT
UC Davis Health tests monoclonal antibodies as potential COVID-19 treatment
UC Davis Health (Defunct)

Timothy Albertson has received a BARDA grant to lead a new clinical trial at UC Davis Health. The trial evaluates the efficacy, safety and tolerability of an antibody cocktail in hospitalized adult patients with COVID-19.

Released: 20-Jul-2020 11:25 AM EDT
Despite Promising Lab Results, Most Precision Medicine Therapies for Mesothelioma Fail in the Clinical Setting
Sbarro Health Research Organization (SHRO)

Malignant mesothelioma (MM) is a lethal cancer mainly caused by exposure to asbestos, for which, unfortunately, no current treatment has proven effective, despite the identification of several promising therapeutic targets over the years.

Released: 20-Jul-2020 8:45 AM EDT
Traditional PTSD Therapy Doesn't Trigger Drug Relapse
Johns Hopkins Medicine

Johns Hopkins researchers have demonstrated that behavior therapy that exposes people to memories of their trauma doesn’t cause relapses of opioid or other drug use, and that PTSD severity and emotional problems have decreased after the first therapy session.

17-Jul-2020 6:05 PM EDT
August’s Special Issue of SLAS Discovery Now Available
SLAS

The August special issue of SLAS Discovery “High-Content Imaging and Informatics” features a special collection of original research and perspectives curated by guest editors Myles Fennell, Ph.D. and Paul A. Johnston, Ph.D of The Society of Biomolecular Imaging and Informatics.

   
Released: 16-Jul-2020 5:50 PM EDT
A New Approach to Tailoring Cancer Therapy: Tapping Into Signaling Activities in Cancer Cells
Weizmann Institute of Science

The Weizmann Institute’s Dr. Ravid Straussman and colleagues developed a method that utilizes cellular signaling to determine the best treatment for a given tumor. The method can help tailor treatments and identify new drug-development targets. In fact, the team has already singled out a gene that serves as a target for treating BRCA-related breast cancers.

Released: 16-Jul-2020 4:05 PM EDT
Use of Pembrolizumab Provided Long-Term Benefits in Patients With Metastatic Melanoma, 10-Year Look Shows
Roswell Park Comprehensive Cancer Center

A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and published today in the journal JAMA Oncology provides new insights into an important question: whether BRAF V600E/K mutation status or previous BRAF inhibitor (BRAFi) therapy with or without a MEK inhibitor (MEKi) affects response to pembrolizumab (brand name Keytruda) in patients with advanced melanoma.

Released: 16-Jul-2020 4:05 PM EDT
New Advances Provide Hope for Alzheimer's Patients
University of Nevada, Las Vegas (UNLV)

Dr. Jeffrey L. Cummings, UNLV research professor and a leading expert on Alzheimer’s disease clinical trials, led a five-year review of all Alzheimer’s drugs in the development pipeline. He says today there is more hope than ever that we'll one day solve Alzheimer’s. The paper, “Alzheimer's disease drug development pipeline: 2020,” was published this week in the journal Alzheimer's & Dementia: Translational Research & Clinical Interventions.

Released: 16-Jul-2020 1:35 PM EDT
CBD may help avert lung destruction in COVID-19
Medical College of Georgia at Augusta University

Cannabidiol, or CBD, may help reduce the cytokine storm and excessive lung inflammation that is killing many patients with COVID-19, researchers say.

Released: 16-Jul-2020 12:45 PM EDT
University of Kentucky’s Sanders-Brown Center on Aging Facilitates First Participant in Worldwide Drug Study
University of Kentucky

Researchers at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) recently screened the first participant in the world for what is known as the AHEAD 3-45 study. This work is looking at a study medication, BAN2401, to determine if it can help prevent worsening memory and thinking among individuals who might be at risk for future decline. They are hoping this study finds that BAN2401 does just that and will ultimately help prevent Alzheimer’s disease.

   
Released: 16-Jul-2020 12:10 PM EDT
Memorial Sloan Kettering Awards and Appointments
Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

Released: 15-Jul-2020 10:05 PM EDT
Different approach needed to ‘buy time’ and tackle COVID-19
University of South Australia

A prominent Australian pharmacologist has called for a new approach to treating COVID-19 as hopes fade of finding an effective vaccine or antiviral before the end of the year.

Released: 15-Jul-2020 6:45 PM EDT
Use of Ketamine for a Non-medical Purpose: Statement from the American Society of Anesthesiologists
American Society of Anesthesiologists (ASA)

The American Society of Anesthesiologists firmly opposes the use of ketamine or any other sedative/hypnotic agent to chemically incapacitate someone for a law enforcement purpose and not for a legitimate medical reason. Ketamine is a potent analgesic, sedative and general anesthetic agent which can elevate blood pressure and heart rate, and can lead to confusion, agitation, delirium, and hallucinations. These effects can end in death when administered in a non-health care setting without appropriately trained medical personnel and necessary equipment.

13-Jul-2020 6:00 AM EDT
Mount Sinai Researchers Discover That Topical Treatment Improves Chronic Plaque Psoriasis
Mount Sinai Health System

Researchers at the Icahn School of Medicine report that roflumilast cream (ARQ-151), which contains a highly potent, selective phosphodiesterase-4 (PDE4) inhibitor demonstrated significant improvements in patients with psoriasis signs and symptoms in as early as two weeks. The phase 2b trial results showed that when patients with plaque psoriasis applied topical roflumilast once-daily they reported clear skin as well as improvement in itch and burden of disease. The results of the paper were published online today in The New England Journal of Medicine.

Released: 15-Jul-2020 4:25 PM EDT
New antiplatelet drug shows promise for treating heart attack
University of Illinois Chicago

Researchers have developed a new drug that prevents blood clots without causing an increased risk of bleeding, a common side effect of all antiplatelet medications currently available. A new study published in the journal Science Translational Medicine describes the drug and its delivery mechanisms and shows that the drug is also an effective treatment for heart attack in animal models.



close
3.29024